Fortis Malar Hospitals Ltd vs Pramodini Medicare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Fortis Malar Hospitals Ltd is ₹ 40.21 as of 23 Oct 15:30 . The P/E Ratio of Fortis Malar Hospitals Ltd changed from 1.9 on March 2024 to 18.9 on March 2026 . This represents a CAGR of 115.06% over 3 yearsThe P/E Ratio of Pramodini Medicare Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 years The Market Cap of Fortis Malar Hospitals Ltd changed from ₹ 103.92 crore on March 2021 to ₹ 78.13 crore on March 2026 . This represents a CAGR of -4.64% over 6 yearsThe Market Cap of Pramodini Medicare Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 years The revenue of Fortis Malar Hospitals Ltd for the Jun '26 is ₹ 0.54 crore as compare to the Mar '26 revenue of ₹ 0.66 crore. This represent the decline of -18.18% The revenue of Pramodini Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Fortis Malar Hospitals Ltd for the Jun '26 is ₹ 0.2 crore as compare to the Mar '26 ebitda of ₹ 0.11 crore. This represent the growth of 81.82% The ebitda of Pramodini Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Fortis Malar Hospitals Ltd changed from ₹ -0.06 crore to ₹ 0.15 crore over 9 quarters. This represents a CAGR of NaN% The net profit of Pramodini Medicare Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The Dividend Payout of Fortis Malar Hospitals Ltd changed from 168.63 % on March 2024 to 0 % on March 2026 . This represents a CAGR of -100.00% over 3 yearsThe Dividend Payout of Pramodini Medicare Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Fortis Malar Hospitals Ltd

Fortis Malar Hospital Limited, formerly known as Malar Hospital Limited was established on April 12, 1989 to set up, manage and operate a multi-specialty hospital.
Company is a subsidiary of Fortis Hospitals Limited and Fortis Healthcare Limited is the Intermediate Holding Company.
Later, the Company changed its name to 'Fortis Malar Hospital Limited' on December 21, 2010.
The Hospital building was owned by a fellow subsidiary, Fortis Health Management Limited (FHML) in early 2008. The hospital founded in 1989, has established itself as one of the largest corporate hospitals in Chennai, providing quality super specialty and multi-speciality healthcare services.
With a total bed-strength of 160, including 40 ICU/CCU/RTU beds, the hospital focuses on providing comprehensive medical care in the areas of Cardiology and Cardiac Surgery, Neuro Surgery, Gynaecology, Orthopedics, Gastroenterology, Neurology, Pediatrics, Diabetics, Nephrology and Internal Medicine All the above departments are fully became operational under phase I of the project.

About Pramodini Medicare Ltd

Pramodini Medicare Limited was originally incorporated on September 12, 2000 as 'Pramodini Medicare Private Limited' with the Registrar of Companies, Andhra Pradesh.
Thereafter, the status of the Company changed to public limited Company and the name was changed to 'Pramodini Medicare Limited' vide fresh certificate of incorporation dated November 12, 2025. Company was originally incorporated in the year 2000 with the objective to provide diagnostic services.
The Company provide a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India. Diagnostic services include a comprehensive range of offerings: (i) 'Radiology' which covers Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), X- ray, Ultrasound with colour doppler, Mammography, DEXA Scan and Intervention Radiology, (ii) 'Clinical Laboratory' which includes Haematology, Micro-Biology, Immunology, Pathology & Bio-Chemistry and (iii) 'Nuclear Medicine' which includes PET-CT (Positron Emission Tomography-Computed Tomography), SPECT (Single Photon Emission Computed Tomography) and Nuclear therapy.

FAQs for the comparison of Fortis Malar Hospitals Ltd and null

Which company has a larger market capitalization, Fortis Malar Hospitals Ltd or Pramodini Medicare Ltd?

Market cap of Fortis Malar Hospitals Ltd is 75 Cr while Market cap of Pramodini Medicare Ltd is 239 Cr

What are the key factors driving the stock performance of Fortis Malar Hospitals Ltd and Pramodini Medicare Ltd?

The stock performance of Fortis Malar Hospitals Ltd and Pramodini Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Fortis Malar Hospitals Ltd and Pramodini Medicare Ltd?

As of October 25, 2026, the Fortis Malar Hospitals Ltd stock price is INR ₹40.21. On the other hand, Pramodini Medicare Ltd stock price is INR ₹108.65.

How do dividend payouts of Fortis Malar Hospitals Ltd and Pramodini Medicare Ltd compare?

To compare the dividend payouts of Fortis Malar Hospitals Ltd and Pramodini Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.